Mumbai, Jan 24 (UNI) Pharma Major, Strides Pharma Science on Friday said its step-down wholly owned subsidiary, Strides Pharma Global Pte.
Limited, Singapore, has received tentative approval for Triamcinolone Acetonide Ointment USP, 0.05 per cent from the United States Food & Drug Administration (USFDA).
While it was amongst the few Competitive Generic Therapy (CGT) designated products for Strides, another generic company received approval prior to our approval.
While it was amongst the few Competitive Generic Therapy (CGT) designated products for Strides, another generic company received approval prior to our approval.
Consequently, the final approval for Strides will be effective 30 May 2020 when the company will launch the product.
According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05 pc is approximately USD 20 Mn.
According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05 pc is approximately USD 20 Mn.
The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc.
in the US market, company said in afiling with BSE.
